Skip to main content

William Blair Initiates Coverage of Bruker with Outperform Rating

NEW YORK (GenomeWeb News) – William Blair initiated coverage of Bruker on Wednesday with an Outperform rating and a Core Growth company profile.

Analyst Amanda Murphy estimated 2011 EPS at $.89 on $1.63 billion in revenues, and 2012 EPS at $1.05 on $1.77 billion in revenues.

In a research note, Murphy cited Bruker's spending on R&D, which she said is higher than its peers on a percentage-of-revenue basis, resulting in strong brand reputation and a "robust" IP portfolio.

She added that the company is "one of the most well-diversified companies on our coverage list" with about 3 percent to 4 percent of total revenues derived from National Institutes of Health funding, and total government funding comprising around 9 percent of company-wide revenues. Future growth opportunities include further penetration into the applied markets and operating margin leverage, Murphy said.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.